This episode is a summary of the 2 main COVID-19 vaccines distributed first in Australia, and how pharmacies in Australia will be involved, coinciding with Flu season 2021

This episode discusses the new NICE draft guidelines, new warnings on Hydrochlorothiazide, new opinions on metformin use in pre-diabetes, a new once weekly insulin is being trialled, and I talk to Bec from Activated Probiotics about Biome Lift. The draft guideline can be viewed at www.nice.org.uk/guidance/gid-ng10069/documents/draft-guideline

A trial to determine medicinal cannabis user's perception of benefit, update on risk of hydroxychloroquine and macrolide combination, theory of immunosuppression for COVID-19 management, and potential barriers to deprescribing as described by GPs.

Apixaban vs rivaroxaban in non-valvular AF, SGLT2 inhibitors and renal dysfunction risk, ACEI and ARBs use and risk of influenza, update on Medadvisor signups, and a free course from the ASHP.

Apixaban study on outcomes regardless of stroke history, glucosamine allergy and effects on blood glucose level, warninhs over low doses of vitamin B6 and how to access products from the SAS.

Updates on mental health during times of COVID-19 including self-care and clozapine, update on Hydroxychloroquine studies, and changes to medscheck and HMR/RMMR programs

An update on why a recommendation was made to avoid ibuprofen in COVID-19 infection, is hydroxychloroquine really the magic drug to rid us of this horrible scourge, and new evidence suggests our elderly patients in isolation may be at an accelerated risk of frailty. Link as mentioned in episode: https://www.cebm.net/covid-19/maximising-mobility-in-the-older-people-when-isolated-with-covid-19/